Progress in the management of primary and recurrent ovarian carcinomatosis with peritonectomy procedure and HIPEC in a high volume centre

References

• Siegel R, Ma J, Zou Z, Jemal A. (2014). Cancer statistics, 2014. CA Cancer J Clin 64:9–29.
   PubMed Web of Science ®Google Scholar
• Ledermann JA, Raja FA, Fotopoulou C, et al. (2013). Newly diagnosed and relapsed epitelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 24 (Suppl 6):v24–33.
   Web of Science ®Google Scholar
• Armstrong DK, Bundy B, Wenzel L, et al. (2006). Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354:34–43.
   PubMed Web of Science ®Google Scholar
• Tewari D, Java JJ, Salani R, et al. (2015). Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cáncer. J Clin Oncol 33:1460–6.
   PubMed Web of Science ®Google Scholar
• Chang SJ, Hodeib M, Chang J, Bristow R. (2013). Survival impact of complete cytoreduction to no gross residual disease for primary-stage ovarian cáncer: a metanalysis. Gynecol Oncol 130:493–8.
   PubMed Web of Science ®Google Scholar
• Huo YR, Richards A, Liauw W, Morris DL. (2015). Hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery (CRS) in ovarian cancer: a systematic review and meta-analysis. Eur J Surg Oncol 41:1578–89.
   PubMed Web of Science ®Google Scholar
• Spiliotis J, Halkia E, Lianos E, et al. (2015). Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III Study. Ann Surg Oncol 22:1570–5.
   PubMed Web of Science ®Google Scholar
• Munoz-Casares FC, Rufian S, Rubio MJ, et al. (2007). Treatment of peritoneal carcinomatosis from ovarian cancer. Present, future directions and proposals. Clin Transl Oncol E 9:652–62.
   PubMed Web of Science ®Google Scholar
• Rufian S, Munoz-Casares FC, Briceno J, et al. (2006). Radical surgery-peritonectomy and intraoperative intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis in recurrent or primary ovarian cancer. J Surg Oncol 94:316–24.
   PubMed Web of Science ®Google Scholar
• Muñoz-Casares FC, Medina-Fernández FJ, Arjona-Sánchez Á, et al. (2016). Peritonectomy procedures and HIPEC in the treatment of peritoneal carcinomatosis from ovarian cancer: long-term outcomes and perspectives from a high-volume center. Eur J Surg Oncol 42:224–33.
   PubMed Web of Science ®Google Scholar
• McGuire WP, Hoskins WJ, Brady MF, et al. (1996). Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334:1–6.
   PubMed Web of Science ®Google Scholar
• Bristow RE, Tomacruz RS, Armstrong DK, et al. (2002). Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20:1248–59.
   PubMed Web of Science ®Google Scholar
• Sugarbaker PH. (1996). Complete parietal and visceral peritonectomy of the pelvis for advanced primary and recurrent ovarian cancer. Cancer Treat Res 81:75–87.
   PubMedGoogle Scholar
• Hoskins WJ, McGuire WP, Brady MF, et al. (1994). The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual ephitelial ovarian carcinoma. Am J Obstet Gynecol 170:974–80.
   PubMed Web of Science ®Google Scholar
• de Bree E, Rosing H, Filis D, et al. (2008). Cytoreductive surgery and intraoperative hyperthermic intraperitoneal chemotherapy with paclitaxel: a clinical and pharmacokinetic study. Ann Surg Oncol 15:1183–92.
   PubMed Web of Science ®Google Scholar
• Piso P, Dahlke MH, Loss M, et al. (2004). Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from ovarian cancer. World J Surg Oncol 2:21–5.
   PubMedGoogle Scholar
• Zanon C, Clara R, Chiappino I, et al. (2004). Cytoreductive surgery and intraperitoneal chemohyperthermia for recurrent peritoneal carcinomatosis from ovarian cancer. World J Surg 28:1040–5.
   PubMed Web of Science ®Google Scholar
• Deraco M, Rossi CR, Pennacchioli E, et al. (2001). Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion in the treatment of recurrent epithelial ovarian cancer: a phase II clinical study. Tumori 87:120–6.
   PubMed Web of Science ®Google Scholar
• Aebi S, Castiglione M. (2009). Newly and relapsed epithelial ovarian carcinoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 20 (Suppl 4):iv21–3.
   Web of Science ®Google Scholar
• Chua TC, Robertson G, Liauw W, et al. (2009). Intraoperative hyperthermic intraperitoneal chemotherapy after cytoreductive surgery in ovarian cáncer peritoneal carcinomatosis: systematic review of current results. J Cancer Res Clin Oncol 135:1637–45.
   PubMed Web of Science ®Google Scholar
• Bijelic L, Jonson A, Sugarbaker PH. (2007). Systematic review of cytoreductive surgery and heated intraoperative intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis in primary and recurrent ovarian cancer. Ann Oncol 18:1943–50.
   PubMed Web of Science ®Google Scholar
• Chi DS, Eisenhauer EL, Land J, et al. (2006). What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? Gynecol Oncol 103:559–64.
   PubMed Web of Science ®Google Scholar
• Aletti GD, Dowdy SC, Gostout BS, et al. (2006). Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstet Gynecol 107:77–85.
   PubMed Web of Science ®Google Scholar
• Muñoz-Casares FC, Rufian S, Rubio MJ, et al. (2009). The role of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC)in the treatment of peritoneal carcinomatosis in recurrent ovarian cáncer. Clin Transl Oncol 11:753–9.
   PubMed Web of Science ®Google Scholar
• Munoz-Casares FC, Rufian S, Arjona-Sanchez A, et al. (2011). Neoadjuvant intraperitoneal chemotherapy with paclitaxel for the radical surgical treatment of peritoneal carcinomatosis in ovarian cancer: a prospective pilot study. Cancer Chemother Pharmacol 68:267–74.
   PubMed Web of Science ®Google Scholar
• Role of intraperitoneal intraoperative chemotherapy with paclitaxel in the surgical treatment of peritoneal carcinomatosis from ovarian cancer. Hyperthermia Versus Normothermia. Available from: https://clinicaltrials.gov/ct2/show/NCT02739698?term=hyperthermia+ovarian&rank =18 [last accessed 26 Oct 2016].
   Google Scholar
• Arjona-Sánchez A, Cadenas-Febres A, Cabrera-Bermon J, et al. (2016). “Assessment of RIFLE and AKIN criteria to define acute renal dysfunction for HIPEC procedures for ovarian and non ovarian peritoneal malignances”. Eur J Surg Oncol 42:869–76.
   PubMed Web of Science ®Google Scholar
• Medina-Fernandez J, Munoz-Casares FC, Arjona-Sanchez A, et al. (2015). Postoperative time course and utility of inflammatory markers in patients with ovarian peritoneal carcinomatosis treated with neoadjuvant chemotherapy, cytoreductive surgery and HIPEC. Ann Surg Oncol 22:1332–40.
   PubMed Web of Science ®Google Scholar
• Meyer LA, Cronin AM, Sun CC, et al. (2016). Use and effectiveness of neoadjuvant chemotherapy for treatment of ovarian cancer. J Clin Oncol 34:3854–63.
   PubMed Web of Science ®Google Scholar
• Vergote I, Trope CG, Amant F, et al. (2010). Neoadjuvant chemotherapy or primary surgery in stage IIIC and IV ovarian cáncer. N Engl J Med 363:943–53.
   PubMed Web of Science ®Google Scholar